About MRC-Holland
MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands. The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by Dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases—purified from a wide range of bacteria and blue green algae—and DNA molecular weight markers. These products were sold in bulk amounts to distributing companies worldwide.

In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis. By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®. The MLPA® technology was first described in Nucleic Acids Research 30, e57 (2002) by Schouten et al. Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.

At present, most activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques. MRC-Holland currently has more than 80 employees, working in development, quality testing, production, sales and customer service.

Quality Management
Quality is very important to MRC-Holland. We have a ISO 13485:2003 certification for the design, development, manufacture and distribution of SALSA MLPA kits. This certificate has been granted by DEKRA Certification B.V., the Netherlands. Our current certificate is valid until 1 March 2019 and can be downloaded here.

One of MRC-Holland's buildings.
new products
Hypophosphatasia (HPP)
Various cancer types
P480-WHS & Achondroplasia
Wolf Hirschhorn Syndrome, Achondroplasia
Meningioma, Coffin-Siris syndrome
improved products
Spinal muscular atrophy (SMA)
Cytochrome P450
PTEN hamartoma tumor syndrome, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related proteus syndrome, Proteus-like syndrome; (Tumour analysis for research use only)
Lynch syndrome; MUTYH-associated polyposis (MAP)
Juvenile polyposis syndrome (JPS)
Propionic acidemia
Susceptibility to breast cancer; Susceptibility to other cancer types
Thyroid dysgenesis
P098-Wilson disease
Wilson disease
Beta-thalassemia; Persistence of foetal haemoglobin, hereditary (HPFH); Sickle cell anaemia (SCA); Sickle cell disease (SCD)
Mismatch repair genes (MMR)
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland